[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  BiopharmIQ by Amp [@BiopharmIQ](/creator/twitter/BiopharmIQ) on x 25.7K followers Created: 2025-07-17 15:39:41 UTC 📣 Biotech Stock News 07/17 @ Open $SRPT XX% Strategic Restructuring & Pipeline Update $RCKT XX% Receives RMAT Designation for Gene Therapy $MBRX XX% Explores Accelerated Strategic Partnerships $DMAC X% Positive Interim Phase X Results $MAIA X% Peer-Reviewed Pub. on Anticancer Prodrugs $AGEN X% FDA Approves SHINGRIX Prefilled Syringe $XXII X% Launch Confirms Viability of Nicotine Mandate $DNA X% Launches ADME Profiling Service $SDGR X% Expand Research Collaboration on JAK Target $PRAX X% FDA Breakthrough Therapy for Relutrigine $CYBN X% UK Approval for EMBRACE Study $NKGN X% New Funding for Compliance and Standards $HROW X% Commercialization Agrmt. for Biosimilars $ALDX X% FDA Review Acceptance for Reproxalap $BMY X% Direct-to-Patient Eliquis Option Announced $RDNT X% Completes Acquisition of iCAD $ACTU X% Advances Clinical Program in Ewing Sarcoma $TXG X% Launch TISHUMAP Study for Drug Discovery $IMAB X% Strengthens Givastomig IP Portfolio $NLSP X% Progress in iTOL-102 Diabetes Program $KROS -X% First Patient Dosing in Phase X Trial $AZN -X% Breakthrough Therapy HER2+ Breast Cancer $JNJ -X% U.S. FDA Priority Review for TAR-200 $BCAB -X% Upcoming Oral Presentation at ESMO TAT $SXTP -X% Research Agreement to Study Tafenoquine $SXTP -X% Closing of up to $XX Million Offering $OKYO -X% Receives $XXX Million in Funding $STXS -X% $XXXX Million Direct Offering $LSTA -X% iLSTA Trial Enrollment Completion Update $CLSD -XX% Explore Strategic Alternatives for SCS Platform See image for more details. 📸 🚨 $SRPT announced a strategic restructuring & pipeline prioritization plan to support long-term growth, & provided an update on ELEVIDYS label. See @PersimmonTI for key PR screenshots. 👇  XXXXX engagements  **Related Topics** [dna](/topic/dna) [maia](/topic/maia) [nicotine](/topic/nicotine) [$xxii](/topic/$xxii) [$agen](/topic/$agen) [$maia](/topic/$maia) [$dmac](/topic/$dmac) [$mbrx](/topic/$mbrx) [Post Link](https://x.com/BiopharmIQ/status/1945871031148876231)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BiopharmIQ by Amp @BiopharmIQ on x 25.7K followers
Created: 2025-07-17 15:39:41 UTC
📣 Biotech Stock News 07/17 @ Open
$SRPT XX% Strategic Restructuring & Pipeline Update $RCKT XX% Receives RMAT Designation for Gene Therapy $MBRX XX% Explores Accelerated Strategic Partnerships $DMAC X% Positive Interim Phase X Results $MAIA X% Peer-Reviewed Pub. on Anticancer Prodrugs $AGEN X% FDA Approves SHINGRIX Prefilled Syringe $XXII X% Launch Confirms Viability of Nicotine Mandate $DNA X% Launches ADME Profiling Service $SDGR X% Expand Research Collaboration on JAK Target $PRAX X% FDA Breakthrough Therapy for Relutrigine $CYBN X% UK Approval for EMBRACE Study $NKGN X% New Funding for Compliance and Standards $HROW X% Commercialization Agrmt. for Biosimilars $ALDX X% FDA Review Acceptance for Reproxalap $BMY X% Direct-to-Patient Eliquis Option Announced $RDNT X% Completes Acquisition of iCAD $ACTU X% Advances Clinical Program in Ewing Sarcoma $TXG X% Launch TISHUMAP Study for Drug Discovery
$IMAB X% Strengthens Givastomig IP Portfolio $NLSP X% Progress in iTOL-102 Diabetes Program
$KROS -X% First Patient Dosing in Phase X Trial $AZN -X% Breakthrough Therapy HER2+ Breast Cancer $JNJ -X% U.S. FDA Priority Review for TAR-200 $BCAB -X% Upcoming Oral Presentation at ESMO TAT $SXTP -X% Research Agreement to Study Tafenoquine $SXTP -X% Closing of up to $XX Million Offering $OKYO -X% Receives $XXX Million in Funding $STXS -X% $XXXX Million Direct Offering $LSTA -X% iLSTA Trial Enrollment Completion Update $CLSD -XX% Explore Strategic Alternatives for SCS Platform See image for more details. 📸
🚨 $SRPT announced a strategic restructuring & pipeline prioritization plan to support long-term growth, & provided an update on ELEVIDYS label. See @PersimmonTI for key PR screenshots. 👇
XXXXX engagements
Related Topics dna maia nicotine $xxii $agen $maia $dmac $mbrx